Hydroxyurea treatment for chronic myeloid leukemia during pregnancy


CELİLOĞLU M., ALTUNYURT S., Undar B.

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, vol.79, no.9, pp.803-804, 2000 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 79 Issue: 9
  • Publication Date: 2000
  • Doi Number: 10.1034/j.1600-0412.2000.079009803.x
  • Journal Name: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.803-804
  • Keywords: chronic myeloid leukemia, hydroxurea treatment, white blood cell count, CHRONIC MYELOGENOUS LEUKEMIA
  • Dokuz Eylül University Affiliated: Yes

Abstract

The incidence of chronic myeloid leukemia (CML) associated with pregnancy is estimated to be 1/75,000. Several types of treatments have been used for CML during pregnancy. These are cytotoxic drugs, alpha-interferone, splenic irradiation (with shielding of the uterus) and leukapheresis. Hydroxyurea is a cytotoxic drug that inhibits the synthesis of DNA and can be used both in the chronic and accelerated phases of CML (1).